[HTML][HTML] Micro and nano-carriers-based pulmonary drug delivery system: Their current updates, challenges, and limitations–A review

M Kumar, AR Hilles, SH Almurisi, A Bhatia, S Mahmood - JCIS Open, 2023 - Elsevier
The lung is an attractive target for drug delivery because of the ease of non-invasive
administration via inhalation, bypassing metabolism in the liver, direct delivery to the …

[HTML][HTML] Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

H Padinharayil, J Varghese, MC John, GK Rajanikant… - Genes & …, 2023 - Elsevier
Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

Exploring the HSA/DNA/lung cancer cells binding behavior of p-Synephrine, a naturally occurring phenyl ethanol amine with anti-adipogenic activity: multi …

R Taheri, N Hamzkanlu, Y Rezvani… - Journal of Molecular …, 2022 - Elsevier
As a phenolic amine, p-Synephrine (SN) is known to exhibit lipolytic properties as well as
enhancing energy expenditure, which can be an excellent alternative to ephedra as a …

Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance

A Ashrafi, Z Akter, P Modareszadeh, P Modareszadeh… - Cancers, 2022 - mdpi.com
Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …

Reprogramming of lipid metabolism in lung cancer: An overview with focus on EGFR-Mutated non-small cell lung cancer

K Eltayeb, S La Monica, M Tiseo, R Alfieri, C Fumarola - Cells, 2022 - mdpi.com
Lung cancer is the leading cause of cancer deaths worldwide. Most of lung cancer cases are
classified as non-small cell lung cancers (NSCLC). EGFR has become an important …

[HTML][HTML] EGFR exon20 insertion mutations in non–small cell lung cancer: Clinical implications and recent advances in targeted therapies

Q Bai, J Wang, X Zhou - Cancer Treatment Reviews, 2023 - Elsevier
The advent of targeted therapies for oncogenic mutations has led to a major paradigm shift
in the management of non–small cell lung cancer (NSCLC). Molecular targets, such as …

Exosomal circular RNA: a signature for lung cancer progression

BM Hussen, SR Abdullah, GS Hama Faraj… - Cancer Cell …, 2022 - Springer
Membrane vesicles having a diameter of 30–150 nm are known as exosomes. Several
cancer types secrete exosomes, which may contain proteins, circular RNAs (circRNAs) …

[HTML][HTML] Ugonin P inhibits lung cancer motility by suppressing DPP-4 expression via promoting the synthesis of miR-130b-5p

CY Wu, SS Ghule, CC Liaw, D Achudhan… - Biomedicine & …, 2023 - Elsevier
Lung cancer is the leading cause of cancer-related death worldwide, and the survival rate of
metastatic lung cancer is exceedingly low. Helminthostatchys Zeylanica (H. Zeylanica) is a …

PSMA expression in solid tumors beyond the prostate gland: ready for theranostic applications?

C Lauri, L Chiurchioni, VM Russo, L Zannini… - Journal of Clinical …, 2022 - mdpi.com
In the past decades, the expanding use of prostate-specific membrane antigen (PSMA)
imaging for prostate cancer has led to the incidental detection of a lot of extra-prostatic …

Vaping, environmental toxicants exposure, and lung cancer risk

SA Shehata, EA Toraih, EA Ismail, AM Hagras… - Cancers, 2023 - mdpi.com
Simple Summary Lung cancer (LC) is considered one of the most common cancers globally.
Numerous studies have determined the relations between E-cigarette, or vaping, products …